These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8516989

  • 21. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.
    Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, Linehan WM, Rosenberg SA.
    Urology; 1993 Sep; 42(3):250-7; discussion 257-8. PubMed ID: 8379024
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma].
    Watanabe J, Hattori T, Satoh M, Akimoto M.
    Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1156-63. PubMed ID: 7609359
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang JC, Linehan WM, Rosenberg SA.
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [Abstract] [Full Text] [Related]

  • 34. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.
    Cancer; 1993 Sep 01; 72(5):1733-42. PubMed ID: 8348502
    [Abstract] [Full Text] [Related]

  • 35. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy.
    Elias L, Hunt WC.
    Oncology; 2001 Sep 01; 61(2):91-101. PubMed ID: 11528247
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.